By Carolyn Timpany, Senior Supplies Manager - International, Lisa Spence, Director, Clinical Supply Chain - International, Ed Groleau, Director, Clinical Supply Chain, North America, PCI Pharma Services
With the number of registered clinical trials increasing significantly each year, it’s not surprising to learn that the clinical trials supply and logistics market is predicted to grow exponentially in the years ahead. Recent data suggests that by 2030 this market will be valued at approximately $12.4 billion, up from $5.1 billion in 2020; this translates to a Compound Annual Growth Rate (CAGR) of 9.1% from 2021 to 2030.1 Such growth places huge pressure on drug discovery companies, CROs and CDMOs to find supply management solutions which ensure seamless, efficient delivery of clinical trial materials worldwide, whilst navigating the challenges of more complex study designs and the ever-evolving regulatory landscape. PCI Pharma Services’ clinicalSMART™ is one such solution.
In this application note, two case studies demonstrate how a clinicalSMART™ Clinical Supply Manager (CSM) provided supply study oversight and managed unblinded IRT activities and drug inventory.